Hemispherian AS Bags NOK 16 Million To develop GLIX Compounds For Cancer

The Research Council of Norway has awarded NOK 16 million to Hemispherian AS, an Oslo-based Norwegian preclinical pharmaceutical business concentrating on small molecule cancer therapies. Hemispherian's GLIX patented chemicals target a unique mechanism shared by all tumors. 

The company's lead drug candidate, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a highly aggressive and most common primary brain cancer, which continues to be one of the highest unmet needs in oncology. The funding awarded is earmarked for the development of Hemispherian's promising drug candidates aimed at treating platinum-resistant ovarian cancers, one of the most challenging gynecological malignancies, as per pharmabiz.

"We are immensely grateful for this support from the Research Council of Norway," said Zeno Albisser, CEO of Hemispherian. "Our team is excited to advance our second asset, GLIX5, towards clinical use. We are dedicated to developing therapies that will make a tangible difference in the lives of those battling cancer."

Hemispherian is a forward-thinking pharmaceutical firm focused on the development of a new class of small molecule medications (GLIX). GLIX chemicals bind to the TET2 enzyme and stimulate the DNA damage response, causing cancer cells to die. GLIX1, the company's flagship product, is in late-stage preclinical development for the treatment of glioblastoma, a lethal central nervous system cancer that is the leading cause of mortality in children. GLIX5 is being developed further by Hemispherian for the treatment of platinum-resistant ovarian malignancies.

Hemispherian is now developing in pre-clinical investigations for the treatment of glioblastoma with their main drug, GLIX1. GLIX5, which is indicated in a considerably larger variety of malignancies, is also in the pipeline and is at the proof of concept stage. We also have two compounds in the late stages of development. Additional compounds are in the early phases of development.